WHY THIS CHARITY MATTERS

Rare cancer isn’t rare. 25% of cancer patients are facing rare cancer. Patients with rare cancers face poor outcomes compared to patients with common cancers. This is because progress requires data and funding, which is traditionally a challenge for rare disease research. Prior to the launch of the Katie Moore Fund, there were two major barriers to progress in rare cancer research: it was impossible for patients with rare cancers at any hospital in the US to donate living samples of their cancer tissue for the creation of cell models, and in the lab, there was no proven strategy to create cell models from any rare tumor with high success rates. The Katie Moore Foundation, partnership with the Broad Institute of MIT & Harvard is changing this.

WHY JOE CHOSE THIS CHARITY

Two years ago, Joe’s best friend of over 25 years was diagnosed with an extremely rare form of sarcoma. Traditional cancer treatments were ineffective, and he recently passed away at the too young age of 54. No one should have to endure the suffering caused by cancer, and while however slow, progress is being made toward effective treatments. Joe’s hope is that anyone fighting rare cancers has a true chance of remission.